<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04048161</url>
  </required_header>
  <id_info>
    <org_study_id>STAMP</org_study_id>
    <nct_id>NCT04048161</nct_id>
  </id_info>
  <brief_title>Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients With Nephrotic Syndrome</brief_title>
  <acronym>STAMP</acronym>
  <official_title>Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome: a Randomized, Multicenter, Open-label, Parallel-arm Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Children's Hospital of Zhejiang University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Zhongshan Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chengdu Women and Children's Center Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Children's Hospital of Zhejiang University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary nephrotic syndrome accounts for approximately 90% of the total number of nephrotic
      syndrome in childhood and it is the most common glomerular disease in children. Although
      treatment with steroids is uesful for primary nephrotic syndrome, proning to cause frequent
      relapse/steroid-dependent nephrotic syndrome after treatment, and the usage of
      immunosuppressive agents has become a new choice for the treatment of such patients. This
      study is a prospective, randomized, multicenter, open, parallel controlled trial, evaluating
      the efficacy and safety of steroid combined with the immunosuppressive agents which are
      tacrolimus and mycophenolate mofetil to children who with frequently relapsing or
      steroid-dependent nephrotic syndrome, all we wish to obtain the proper drug choice and
      individualized treatment options for children with nephrotic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although steroids are recognized as first-line treatments for nephrotic syndrome, the vast
      majority of children relapse, and about half of them have frequent relapse or steroids
      dependence after treatment with steroids alone. Some children experienced steroids-resistance
      after multiple relapses, and eventually developed into chronic kidney dysfunction. Long-term
      or repeated application of large doses of steroids will lead to side effects such as obesity,
      growth retardation, and hypertension. Although the treatment of steroids with
      immunosuppressive agents is a new choice for the treatment of such patients, traditional
      immunosuppressive agents such as cyclophosphamide and cyclosporine A will bring some serious
      irreversible side effects, while immunosuppressive agents tacrolimus has the dual effects of
      immunosuppression and podocyte protection, and is more widely used in the department of
      nephrology, what's more, the other immunosuppressive agents mycophenolate mofetil has
      advantage of no kidney toxic, less adverse reactions and higher safety, which gradually being
      valued by nephrologists in recent years. This study mainly compares the efficacy and safety
      of tacrolimus and mycophenolate mofetil in the treatment of children with frequently
      relapsing or steroids-dependent nephrotic syndrome, in order to provide a more effective and
      safer treatment for children with nephrotic syndrome as well as the therapeutic medication
      options.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year relapse-free survival rate</measure>
    <time_frame>1-year period after randomization</time_frame>
    <description>The rate of no relapse within 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse of nephrotic syndrome during 12 months after randomization</measure>
    <time_frame>1-year period after randomization</time_frame>
    <description>Proportion of patients with one or more relapse(s) of nephrotic syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapses during 12 months follow up</measure>
    <time_frame>1-year period after randomization</time_frame>
    <description>Number of nephrotic syndrome relapses per patient year during the 12 months period after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The first time to relapse</measure>
    <time_frame>1-year period after randomization</time_frame>
    <description>The first time to relapse after patients taking part in this study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative prednisone dosage (milligrams per kilogram per year)</measure>
    <time_frame>1-year period after randomization</time_frame>
    <description>The total dosage of prednisones from the beginning to the end of the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum cholesterol, hemoglobin and blood albumin of the patients</measure>
    <time_frame>1-year period after randomization</time_frame>
    <description>The changes of serum cholesterol, hemoglobin and blood albumin in each follow-up during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal function of the patients</measure>
    <time_frame>1-year period after randomization</time_frame>
    <description>The change for renal function was judged by the changes of serum creatinine and estimated glomerular filtration rate in each follow-up during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anthropometry and growth velocity during 12-month period after randomization</measure>
    <time_frame>1-year period after randomization</time_frame>
    <description>Changes in standard deviation scores for weight, height and body mass index during 12-month period after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>1-year period after randomization</time_frame>
    <description>The number of harmful reactions and the types of adverse events during the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Nephrotic Syndrome in Children</condition>
  <arm_group>
    <arm_group_label>Tacrolimus(Group A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus: 0.5mg and 1mg; Capsule; 0.05-0.10mg/kg/day，BID; Steroid: 5mg; Oral tablets; 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mycophenolate Mofetil(Group B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mycophenolate Mofetil: 250mg; Dispersible tablets; 20~30mg/kg/day，BID; Steroid: 5mg; Oral tablets; 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>The patients will be divided into two groups randomly. Tacrolimus dose: 0.05-0.10 mg/kg/day, BID. The concentration for tacrolimus is 5-10 ng/ml，then reduce the dosage of drugs to maintian the concentration for tacrolimus is &lt; 5ng/ml. Total duration : 1 year.
Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day.</description>
    <arm_group_label>Tacrolimus(Group A)</arm_group_label>
    <other_name>Tacrolimus capsules（CYONSE®）</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>The patients will be divided into two groups randomly. Mycophenolate Mofetil dose: 20~30mg/kg/day，BID. The concentration for MPA-AUC is 30~50 μg.h/ml，then reduce the dosage of drugs to maintian the concentration for MPA-AUC is ≤40 μg.h/ml. Total duration : 1 year.
Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day.</description>
    <arm_group_label>Mycophenolate Mofetil(Group B)</arm_group_label>
    <other_name>Mycophenolate Mofetil Dispersible tablets（CYCOPIN®）</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sensitive but frequent relapses or steroids dependence nephrotic syndrome

          -  Age: 2 to 18 years old

          -  Normal renal function: estimated glomerular filtration rate ≥90ml/min/1.73m2

          -  Morning urine protein &lt;1+ or urine protein-creatinine ratio &lt;0.2g/g (&lt;20 mg/mmol) for
             3 consecutive days and above when in enroll

          -  No tacrolimus, mycophenolate mofetil, cyclosporine A, rituximab or cyclophosphamide
             was used within 2 years prior to the enrollment

        Exclusion Criteria:

          -  steroids-resistant nephrotic syndrome

          -  Family history of nephrotic syndrome, chronic glomerulonephritis or uremia

          -  Leukopenia (White Blood Cells ≤ 3.0 * 10^9 / L)

          -  Moderate to severe anemia (hemoglobin &lt;9.0 g/dL)

          -  Thrombocytopenia (platelet count &lt;100*10^12/L)

          -  Positive Hepatitis B virus serological indicators (Hepatitis B surface antigen or /
             and Hepatitis B virus e antigen or / and Hepatitis B core antibody), Hepatitis C
             virus-positive or patients with abnormal liver function (2 or more times of alamine
             aminotransferase or total bilirubin was exceeded the normal value, and continued to
             rise for 2 weeks)

          -  There are chronic active infections such as Epstein-Barrvirus, cytomegalovirus or
             Mycobacterium tuberculosis, and the usage of steroids and immunosuppressive agents may
             aggravate the state of an illness

          -  Secondary nephrotic syndrome (such as purpuric nephritis, lupus nephritis, etc.)

          -  Those who with hematological or endocrine system diseases as well as serious organs
             illness such as heart, liver or kidney

          -  Those who with other autoimmune diseases or primary immunodeficiencies or tumors

          -  Those who was known to be sensitized to tacrolimus, mycophenolate mofetil,
             glucocorticoids, or any of the above drugs

          -  Those who have participated in other clinical trials within three months prior to the
             enrollment

          -  Those who was not suitable for participating this study judged by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianhua Mao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital, Zhejiang University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianhua Mao, MD</last_name>
    <phone>0571-87061007</phone>
    <email>maojh88@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jie Ding, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jie Ding, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Chongqing University of Medical Sciences</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>401122</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mo Wang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mo Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Zhongshan Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyun Jiang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Xiaoyun Jiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhua Zhou, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jianhua Zhou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaochuan Wu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Xiaochuan Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing Children's Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fei Zhao, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fei Zhao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201102</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Xu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hong Xu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chengdu Women and Children's Center Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Shichuan</state>
        <zip>610043</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shipin Feng, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shipin Feng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhua Mao, MD</last_name>
      <phone>0571-87061007</phone>
      <email>maojh88@126.com</email>
    </contact>
    <investigator>
      <last_name>Jianhua Mao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jingjing Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Ren H, Shen P, Li X, Pan X, Zhang W, Chen N. Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: a randomized controlled trial. Am J Nephrol. 2013;37(1):84-90. doi: 10.1159/000346256. Epub 2013 Jan 22.</citation>
    <PMID>23343906</PMID>
  </results_reference>
  <results_reference>
    <citation>Filler G, Young E, Geier P, Carpenter B, Drukker A, Feber J. Is there really an increase in non-minimal change nephrotic syndrome in children? Am J Kidney Dis. 2003 Dec;42(6):1107-13. Review.</citation>
    <PMID>14655180</PMID>
  </results_reference>
  <results_reference>
    <citation>Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003 Aug 23;362(9384):629-39. Review.</citation>
    <PMID>12944064</PMID>
  </results_reference>
  <results_reference>
    <citation>Wong W. Idiopathic nephrotic syndrome in New Zealand children, demographic, clinical features, initial management and outcome after twelve-month follow-up: results of a three-year national surveillance study. J Paediatr Child Health. 2007 May;43(5):337-41.</citation>
    <PMID>17489822</PMID>
  </results_reference>
  <results_reference>
    <citation>Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol. 1997 May;8(5):769-76.</citation>
    <PMID>9176846</PMID>
  </results_reference>
  <results_reference>
    <citation>Shaw KT, Ho AM, Raghavan A, Kim J, Jain J, Park J, Sharma S, Rao A, Hogan PG. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11205-9.</citation>
    <PMID>7479966</PMID>
  </results_reference>
  <results_reference>
    <citation>Koefoed-Nielsen PB, Karamperis N, Højskov C, Poulsen JH, Jørgensen KA. The calcineurin activity profiles of cyclosporin and tacrolimus are different in stable renal transplant patients. Transpl Int. 2006 Oct;19(10):821-7.</citation>
    <PMID>16961774</PMID>
  </results_reference>
  <results_reference>
    <citation>Neidle S, Goodwin GH. A homology-based molecular model of the proline-rich homeodomain protein Prh, from haematopoietic cells. FEBS Lett. 1994 May 30;345(2-3):93-8. Review.</citation>
    <PMID>7911091</PMID>
  </results_reference>
  <results_reference>
    <citation>Sepe V, Libetta C, Giuliano MG, Adamo G, Dal Canton A. Mycophenolate mofetil in primary glomerulopathies. Kidney Int. 2008 Jan;73(2):154-62. Epub 2007 Nov 7. Review.</citation>
    <PMID>17989649</PMID>
  </results_reference>
  <results_reference>
    <citation>Briggs WA, Choi MJ, Scheel PJ Jr. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis. 1998 Feb;31(2):213-7.</citation>
    <PMID>9469489</PMID>
  </results_reference>
  <results_reference>
    <citation>Gellermann J, Weber L, Pape L, Tönshoff B, Hoyer P, Querfeld U; Gesellschaft für Pädiatrische Nephrologie (GPN). Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol. 2013 Oct;24(10):1689-97. doi: 10.1681/ASN.2012121200. Epub 2013 Jun 27.</citation>
    <PMID>23813218</PMID>
  </results_reference>
  <results_reference>
    <citation>Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am. 1987 Jun;34(3):571-90.</citation>
    <PMID>3588043</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 30, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Children's Hospital of Zhejiang University School of Medicine</investigator_affiliation>
    <investigator_full_name>Mao Jianhua</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>Nephrotic Syndrome</keyword>
  <keyword>Frequently Relapsing Nephrotic Syndrome</keyword>
  <keyword>Steroid Dependent Nephrotic Syndrome</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Mycophenolate mofetil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We could not share data without patients' agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

